[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367846-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367846-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","protease-activated-receptor-f2r-is-a-potential-target-for-new-diagnosticprognostic-and-treatment-applications-for-patients-with-ovarian-cancer","Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer","","Effective treatment of ovarian cancer is limited by late-stage detection and chemotherapy resistance, creating a clear need for new molecular targets that enable innovative theranostic strategies. This study evaluates coagulation factor II receptor/protease-activated receptor 1 (F2R/PAR1) as a diagnostic/prognostic biomarker and therapeutic target. Public RNA and DNA microarray data were used to assess F2R expression, with protein validation in tumors via flow cytometry, immunofluorescence, and IHC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/protease-activated-receptor-f2r-is-a-potential-target-for-new-diagnosticprognostic-and-treatment-applications-for-patients-with-ovarian-cancer/367846/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/protease-activated-receptor-f2r-is-a-potential-target-for-new-diagnosticprognostic-and-treatment-applications-for-patients-with-ovarian-cancer/367846.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is finding new diagnostic and treatment targets important for ovarian cancer?","Question",{"text":63,"@type":64},"Effective therapy is constrained by late-stage detection and chemotherapy resistance, and patients often experience recurrence. The study emphasizes the clinical need for actionable molecular targets to support improved theranostic approaches.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study measure F2R expression in ovarian cancer?",{"text":68,"@type":64},"It used public RNA sequence and DNA microarray datasets to analyze F2R gene expression. Protein expression in tumor samples was confirmed using flow cytometry, immunofluorescence, and immunohistochemistry (IHC).",{"name":70,"@type":61,"acceptedAnswer":71},"What did F2R suppression show in ovarian cancer models?",{"text":72,"@type":64},"Functional assays indicated that suppressing F2R reduced tumor cell motility, invasion, spheroid formation, and metabolism, while enhancing carboplatin sensitivity. High F2R protein detection was also associated with reduced progression-free survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367846,1790663609,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nProtease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer  \nRiya Khetan 1, Noor A. Lokman 2, Preethi Eldi 3, Zoe K. Price 2, Martin K. Oehler 2,4, Doug A. Brooks 3, Anton Blencowe 1,5, Sanjay Garg 1, Carmela Ricciardelli 2, * and Hugo Albrecht 1, *  \nAcademic Editors: Vladimir Isachenko and Peter J. K. Kuppen  \nReceived: 7 July 2025  \nRevised: 28 August 2025  \nAccepted: 28 August 2025  \nPublished: 2 September 2025  \nCitation: Khetan, R.; Lokman, N.A.; Eldi, P.; Price, Z.K.; Oehler, M.K.; Brooks, D.A.; Blencowe, A.; Garg, S.; Ricciardelli, C.; Albrecht, H. ProteaseActivated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. Int. J. Mol. Sci. 2025, 26, 8529. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26178529](doi.org/10.3390/ijms26178529)  \n[Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Centre of Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia,  \nAdelaide, SA 5000, Australia; [riya.khetan@mymail.unisa.edu.au](riya.khetan@mymail.unisa.edu.au) (R.K.); [anton.blencowe@unisa.edu.au](anton.blencowe@unisa.edu.au) (A.B.); [sanjay.garg@unisa.edu.au](sanjay.garg@unisa.edu.au) (S.G.)  \n2 Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA 5000, Australia; [noor.lokman@adelaide.edu.au](noor.lokman@adelaide.edu.au) (N.A.L.); [zoe.price@adelaide.edu.au](zoe.price@adelaide.edu.au) (Z.K.P.); [martin.oehler@adelaide.edu.au](martin.oehler@adelaide.edu.au) (M.K.O.)  \n3 UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia; [preethi.eldi@unisa.edu.au](preethi.eldi@unisa.edu.au) (P.E.); [doug.brooks@unisa.edu.au](doug.brooks@unisa.edu.au) (D.A.B.)  \n4 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia  \n5 Applied Chemistry and Translational Biomaterials Group, Centre of Pharmaceutical Innovation, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia  \n* Correspondence: [carmela.ricciardelli@adelaide.edu.au](carmela.ricciardelli@adelaide.edu.au) (C.R.); [hugo.albrecht@unisa.edu.au](hugo.albrecht@unisa.edu.au) (H.A.)  \nAbstract  \nEffective treatment of ovarian cancer is limited by late-stage detection and chemotherapy resistance. There is a clinical need for the discovery of novel molecular targets to enable the development of innovative theranostic approaches. We investigated the coagulation factor II receptor/protease-activated receptor 1 (F2R/PAR1) as a potential diagnostic/prognostic biomarker and therapeutic target for ovarian cancer treatment. Public RNA sequence and DNA microarray data were used to analyze F2R gene expression in ovarian cancers, with protein expression confirmed in tumor samples by flow cytometry, immunofluorescence, and immunohistochemistry (IHC). Functional assays were conducted to study effects of F2R suppression on tumor progression. Our analysis confirmed elevated F2R mRNA and protein expression in ovarian cancers, notably in patients with metastatic and chemotherapy-resistant disease. Kaplan–Meier survival analysis demonstrated an association between high F2R protein detection and reduced progression-free survival. F2R suppression in ovarian cancer cell lines reduced tumor cell motility, invasion, spheroid formation, and metabolism and enhanced carboplatin sensitivity. F2R is a compelling diagnostic/prognostic and therapeutic target that could be used to treat chemotherapy-resistant and metas","cbCairxpqXPXaXOC","https://ap.wps.com/l/cbCairxpqXPXaXOC","pdf",4593639,17,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Ovarian cancer burden and need for targets\n## Background: PAR1/F2R biology and activation\n## Rationale for investigating F2R in ovarian cancer","[{\"question\":\"Why is finding new diagnostic and treatment targets important for ovarian cancer?\",\"answer\":\"Effective therapy is constrained by late-stage detection and chemotherapy resistance, and patients often experience recurrence. The study emphasizes the clinical need for actionable molecular targets to support improved theranostic approaches.\"},{\"question\":\"How did the study measure F2R expression in ovarian cancer?\",\"answer\":\"It used public RNA sequence and DNA microarray datasets to analyze F2R gene expression. Protein expression in tumor samples was confirmed using flow cytometry, immunofluorescence, and immunohistochemistry (IHC).\"},{\"question\":\"What did F2R suppression show in ovarian cancer models?\",\"answer\":\"Functional assays indicated that suppressing F2R reduced tumor cell motility, invasion, spheroid formation, and metabolism, while enhancing carboplatin sensitivity. High F2R protein detection was also associated with reduced progression-free survival.\"}]","Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer | PDF",1790172965,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6aef2869271afdcf5dd9314cb642c0b.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d70f58155de9f331ea08dffc5bf84239.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4911842753ccf8d66d3652bb7713e1f.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94759ec12639b4b40a035e0f8ab0e11a.webp",980,1385]